Skip to main content
PERCHERON THERAPEUTICS LIMITED logo

PERCHERON THERAPEUTICS LIMITED — Investor Relations & Filings

Ticker · PER ISIN · AU0000317281 LEI · 984500FF63A961E0K787 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,206 across all filing types
Latest filing 2018-10-28 AGM Information
Country AU Australia
Listing ASX PER

About PERCHERON THERAPEUTICS LIMITED

https://percherontx.com

Percheron Therapeutics Limited is a clinical-stage company focused on the development of novel antisense pharmaceuticals for rare diseases. The company's lead program, ATL1102, is an antisense oligonucleotide targeting the CD49d receptor, a subunit of the VLA-4 integrin. This therapeutic candidate is primarily being developed for the treatment of Duchenne muscular dystrophy (DMD), where it aims to reduce inflammation and muscle damage by modulating the immune system's response. Formerly known as Antisense Therapeutics, the firm utilizes its proprietary antisense technology platform to create targeted therapies that inhibit the production of proteins associated with disease progression. The company's research and development efforts are centered on addressing significant unmet medical needs through precision genetic medicine.

Recent filings

Filing Released Lang Actions
Notice of Annual General Meeting/Proxy Form 86 pages 4.4MB
AGM Information Classification · 100% confidence The document is titled 'NOTICE OF ANNUAL GENERAL MEETING' and includes details about the meeting date, location, and agenda. It mentions the dispatch of the Notice of AGM, Explanatory Notes, Proxy Form, and Annual Report to shareholders. The document contains resolutions to be voted on at the AGM, including adoption of the Remuneration Report, re-election of a director, ratification of share issues, and approval of a placement facility. It also includes detailed proxy voting instructions and legal references to the Corporations Act. The document is a formal notice to shareholders about the upcoming AGM and the matters to be considered, rather than the actual Annual Report or other financial statements. It is comprehensive and over 15,000 characters, indicating it is not a brief announcement but the full notice document. Therefore, the correct classification is AGM Information (AGM-R).
2018-10-28 English
Response to ASX Price and Volume Query 5 pages 170.6KB
Regulatory Filings Classification · 100% confidence The document is a letter from ASX Compliance to Antisense Therapeutics Limited regarding a query about unusual price and volume movements in the company's securities. The letter requests the company to confirm whether it is aware of any undisclosed information that could explain the trading activity and to confirm compliance with ASX Listing Rules, particularly Listing Rule 3.1 on continuous disclosure. The company's response confirms no undisclosed information and compliance with Listing Rules. This type of document is a regulatory compliance response to a market query, not a financial report, earnings release, or management discussion. It is a regulatory filing related to market disclosure obligations and compliance with listing rules. The document is not a report publication announcement, nor does it contain financial data or executive changes. Therefore, the appropriate classification is Regulatory Filings (RNS).
2018-10-15 English
Duchenne ACTT Now Conference 2018 2 pages 118.6KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 6th September 2018 regarding Antisense Therapeutics Limited's attendance and presentation at the Duchenne ACTT Now Conference 2018. It provides background information about the conference, the company, and the disease Duchenne Muscular Dystrophy (DMD). There is no financial data, no report attached or referenced as being published, no voting results, no management changes, no earnings data, and no regulatory or legal updates. The document is essentially an event announcement and company participation notice. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Investor Presentation. It is not a report publication announcement since it does not mention any report release. The best fitting category is Regulatory Filings (RNS) as a general announcement that does not fit other specific categories.
2018-09-05 English
Pause in Trading 1 page 112.9KB
Regulatory Filings Classification · 95% confidence The document is a brief market release announcing a temporary pause in trading of the company's securities. It is very short (347 characters) and does not contain any financial data, report content, or detailed information. It is an announcement related to trading status rather than a financial report or detailed filing. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2018-08-28 English
First Patient Dosed in Phase II DMD Clinical Trial 2 pages 126.3KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 29 August 2018 from Antisense Therapeutics regarding the dosing of the first patient in a Phase II clinical trial for a drug targeting Duchenne Muscular Dystrophy (DMD). The content focuses on the clinical trial progress, drug mechanism, and company statements about the trial milestone. There are no financial statements, regulatory certifications, or detailed financial performance data. The document is a corporate announcement about a clinical trial milestone rather than a financial report or regulatory filing. It is not a report publication announcement since it contains substantive information about the trial progress and company outlook. The document fits best as a Regulatory Filing (RNS) because it is a general regulatory announcement about company progress that does not fit into other specific categories such as earnings release, capital update, or management report.
2018-08-28 English
Full Year Statutory Accounts 71 pages 1.1MB
Annual Report Classification · 100% confidence The document is titled 'Antisense Therapeutics Limited Appendix 4E Audited Financial Report Year Ended 30 June 2018' and contains detailed financial results for the full fiscal year ended 30 June 2018. It includes comprehensive financial statements such as the Consolidated Statement of Profit or Loss, Statement of Financial Position, Statement of Changes in Equity, and Cash Flows, as well as notes to the financial statements, directors' report, auditor's report, and corporate governance statement. The document also contains extensive operational and clinical trial information, typical of a full annual report. The presence of an independent auditor's report and detailed financial data confirms this is the full Annual Report. The length (15,000 characters) and depth of content further support classification as a full Annual Report rather than a brief announcement or summary. Therefore, the correct classification is Annual Report (10-K). FY 2018
2018-08-28 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.